Archimedes Pharma UK
1996
FOUNDED
M&A
STATUS
21-30
EMPLOYEES
Buyout/LBO
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Provider of pharmaceutical products. The company offers Gliadel, a treatment for high-grade gliomas; Zomorph for cancer pain; Nozinan, an anti-emetic for nausea and vomiting in advanced cancer patients; and Pabrinex, a high-potency formulation of vitamins B and C for chronic alcoholics. It operates in the United Kingdom, France, and Germany.
Website
Formerly Known As
Link Holdings
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Other Healthcare Services
Other Industries
Pharmaceuticals
Acquirer
Primary Office
- 250 South Oak Way
- Green Park
- Reading RG2 6UG
- England
+44 0118 000 0000
Archimedes Pharma UK Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Archimedes Pharma UK‘s full profile, request access.
Request full access to PitchBook